Antrum R M, Bibby S R, Ramsden C H, Kester R C
Department of Vascular Surgery, St. James's University Hospital, Leeds, UK.
Drugs Exp Clin Res. 1989;15(1):21-3.
Teicoplanin is a new antibiotic currently undergoing clinical evaluation. Consecutive patients undergoing elective vascular surgery (n = 28) were randomised to receive a single intravenous bolus of 400 mg teicoplanin 1, 3, 6 or 12 h prior to surgery as prophylaxis against Gram-positive infection. Serum and fat antibiotic levels were measured and found to exceed the established MICs for common staphylococcal and streptococcal infections for at least 12 h following administration. This suggests that teicoplanin would be a useful choice of antibiotic in the prophylaxis and treatment of appropriate infections in elective surgery. By extrapolation, teicoplanin would also be of use in the prophylaxis and treatment of suitable infections seen in traumatised patients.
替考拉宁是一种目前正在进行临床评估的新型抗生素。连续28例接受择期血管手术的患者被随机分组,在手术前1、3、6或12小时接受单次静脉推注400mg替考拉宁,以预防革兰氏阳性菌感染。测量血清和脂肪中的抗生素水平,发现给药后至少12小时,这些水平超过了常见葡萄球菌和链球菌感染的既定最低抑菌浓度。这表明替考拉宁在择期手术中预防和治疗适当感染时将是一种有用的抗生素选择。由此推断,替考拉宁在预防和治疗创伤患者中出现的合适感染方面也将有用。